Company Overview and News

 
KLCI stays negative, falls 0.43%

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI remained in the negative zone at the midday break today, and fell 0.43% in line with the decline at regional markets.
UPBMF 5088 7113 5010 TPGVF 5202 2089 9334 6033 5199 9113 TGLVY 0143 5139 4588 PNADF 3867 0900 6888 AXXTF 2836 HIPEF PNAGF

 
Apex shares hit limit-up, rallies 26%

2018-10-03 thestar.com.my
The proposed merger comes a year after the entry of an entity called ACE Investment Bank into Apex. The entity emerged with a 23% stake in Apex at about the time when a similar sized block was traded off-market by the late Chan Guan Seng(pic), Apex’s former executive chairman and parties close to him. The share price of Apex then was around RM2 apiece.
5088

 
Apex surges 29.5 sen to hit limit up

2018-10-03 thestar.com.my
KUALA LUMPUR: Apex Equity Holdings Bhd has hit limit up after surging 29.5 sen or 31% to RM1.24. At 3.40pm, trading volume hit 330,600 shares as compared with 32,000 shares traded in the previous session. While the reason for the rapid advance in share price remains unknown, Apex has announced plans to merge its business with another stockbroking firm.
5088

 
KLCI seen trending sideways, immediate support at 1,786

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI is expected to trend sideways today with immediate support at 1,786.
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
George Kent, Axiata, Astro, Bumi Armada, United Malacca, Poh Huat, MAHB, Apex Equity, Poh Kong, Hai-O and Eversendai

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
Are Apex shareholders getting a good deal?

2018-09-23 thestar.com.my
The proposed merger comes a year after the entry of an entity called ACE Investment Bank into Apex. The entity emerged with a 23% stake in Apex at about the time when a similar sized block was traded off market by the late Chan Guan Seng(pic), Apex’s former executive chairman and parties close to him. The share price of Apex then was around RM2 a piece.
4898 1155 1023 1015 MLYBY MLYNF 5088 AMMHF CIMDF

 
Apex proposes merger with Mercury Securities

2018-09-22 thestar.com.my
KUALA LUMPUR: Apex Equity Holdings Bhd has entered into a heads of agreement (HoA) for a proposed merger with Mercury Securities Sdn Bhd.
5088 BSMAF 1818

 
MAHB, United Plantations, Utusan, TM, Binasat, KESM, NTPM, Country Heights and MNRB

2018-09-21 theedgemarkets
KUALA LUMPUR (Sep 21): Based on corporate announcements and news flow today, stocks in focus for Monday (Sep 24) may include the following: Malaysia Airports Holdings Bhd, United Plantations Bhd, Utusan Melayu (Malaysia) Bhd, Telekom Malaysia Bhd, Binasat Communications Bhd, KESM Industries Bhd, NTPM Holdings Bhd, Country Heights Holdings Bhd and MNRB Holdings Bhd.
UPBMF 5066 5088 2089 5014 9334 5754 4863 5738 6459 MYPRY MYTEF 1902

 
Mercury Securities to merge with Apex in RM140m deal

2018-09-21 theedgemarkets
KUALA LUMPUR: Apex Equity Holdings Bhd is proposing a merger with Mercury Securities Sdn Bhd through a RM140 million cash plus share deal.
5088 BSMAF 1818

 
Apex Equity, Mercury Securities to merge in RM140mil deal

2018-09-21 thestar.com.my
KUALA LUMPUR: Apex Equity Holdings Bhd and Mercury Securities Sdn Bhd have entered into a heads of agreement (HOA) to merge their stockbroking operations.
5088 BSMAF 1818

 
Authorisation needed for share buy-backs — lawyers

2018-08-13 theedgemarkets
KUALA LUMPUR: The purchase of its own shares by a public listed company is only valid if the company is authorised to do so by its constitution or memorandum and articles of association (M&A), say lawyers.
5088 BSMAF 1818

1
KLCI to trade range bound, move between 1,790 – 1,800

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 2): The FBM KLCI is expected to trade range bound today within a tight band of between 1,790 – 1,800.
5216 5754 6556 AAPL 5088 8117 0098 5254

 
DRB-Hicom, Malakoff, Bahvest, Boustead Plantations, LKL, MHB, Ann Joo, Utusan, Poly Glass Fibre, Datasonic, Apex Equity and AirAsia

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Based on corporate announcements and news flow today, companies in focus on Thursday (Aug 2) may include: DRB-Hicom Bhd, Malakoff Corp Bhd, Borneo Aqua Harvest Bhd, Boustead Plantations Bhd, LKL International Bhd, Malaysia Marine and Heavy Engineering Holdings Bhd, Ann Joo Resources Bhd, Utusan Melayu (Malaysia) Bhd, Poly Glass Fibre (M) Bhd, Datasonic Group Bhd, Apex Equity Holdings Bhd and AirAsia Group Bhd.
5216 5754 6556 5088 MYPRY 8117 5014 0098 5254

 
Apex Equity files court application over 'questionable' corporate exercises

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Apex Equity Holdings Bhd said it is seeking a validation order from the High Court, to regularise its previous share buy-back exercises.
5088

 
KLCI edges up as regional markets stay nervous

2018-07-05 theedgemarkets
KUALA LUMPUR (July 5): The FBM KLCI edged up marginally this morning against the backgroup of nervous regional markets.
5088 7113 TPGVF 7153 TGLVY 4863 5347 5225 TNABY MYTEF TNABF Q0F IHHHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...